Argon plasma coagulation is an effective treatment for chronic radiation proctitis in gynaecological malignancy: an observational study. (22nd January 2019)

• Record Type: Journal Article
• Authors: Sultania, S.; Sarkar, R.; Das, K.; Dhali, G. K.
• Is Part Of: Colorectal disease. Volume 21:Number 4(2019)
• Page Start: 465
• Page End: 471
• Publication Date: 2019-01-22
• Subjects: Argon plasma coagulation -- chronic radiation proctitis -- rectal bleeding -- anaemia; Colon (Anatomy) -- Diseases -- Periodicals; Rectum -- Diseases -- Periodicals; 616.34
• DOI: 10.1111/codi.14541
• Languages: English
• ISSNs: 1462-8910

Abstract

Abstract: Aim: Chronic radiation proctitis (CRP) develops in 5–15% of patients after pelvic radiation therapy, with rectal bleeding being the main symptom. Reports suggest that argon plasma coagulation (APC) can be an effective therapy for CRP following radiotherapy for prostate cancer, but there is less information about how useful it is after radiotherapy for gynaecological malignancy. The aim of this work therefore was to study the efficacy of APC for CRP after radiotherapy for gynaecological malignancy. Method: This was a prospective study of consecutive patients with CRP following radiotherapy for gynaecological malignancy at IPGME&R, SDLD, Kolkata, India; symptoms included rectal bleeding grade (RBG) ≥ 2. APC was performed at monthly intervals to a maximum of four treatment sessions. Severity of disease at baseline was graded (endoscopically) by the total colonoscopic severity score (TCSS) and treatment response was assessed by reduction in RBG from ≥ 2 to ≤ 1 measured at > 6 months after cessation of APC. Results: Seventy patients [90% with cervical cancer, 10% with endometrial cancer; mean age 51.93 ± 9.15 years; median RBG 3 (range 2–4)] received APC. Seven patients died due to underlying malignancy and seven patients were lost to follow‐up. Fifty‐six (85.7%) patients responded to therapy after a median of 2 (range 1–4) treatment sessions. Multivariate analysis demonstrated that a lower haemoglobin at the start of treatment predicted failure of therapy ( P < 0.05). Conclusion: APC is an effective management option for CRP in female patients with gynaecological malignancy. However, the more anaemic the patient the less likely it is to be successful.